vs
Side-by-side financial comparison of Core Laboratories Inc. (CLB) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $121.8M, roughly 1.0× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs 3.3%, a 0.9% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -1.4%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $517.0K). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -3.4%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
CLB vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $121.8M | $123.8M |
| Net Profit | $5.1M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | 1.5% | 4.3% |
| Net Margin | 4.2% | 3.3% |
| Revenue YoY | -1.4% | 4.7% |
| Net Profit YoY | — | 1379.4% |
| EPS (diluted) | $0.11 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $123.8M | ||
| Q3 25 | $134.5M | $128.3M | ||
| Q2 25 | $130.2M | $114.8M | ||
| Q1 25 | $123.6M | $113.2M | ||
| Q4 24 | $129.2M | $118.2M | ||
| Q3 24 | $134.4M | $114.6M | ||
| Q2 24 | $130.6M | $110.6M |
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | $4.1M | ||
| Q3 25 | $14.2M | $5.3M | ||
| Q2 25 | $10.6M | $5.3M | ||
| Q1 25 | $-154.0K | $4.7M | ||
| Q4 24 | $7.4M | $-321.0K | ||
| Q3 24 | $11.7M | $4.3M | ||
| Q2 24 | $9.0M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | 72.5% | ||
| Q3 25 | 22.0% | 73.3% | ||
| Q2 25 | 20.3% | 71.7% | ||
| Q1 25 | 19.5% | 72.1% | ||
| Q4 24 | 17.8% | 72.0% | ||
| Q3 24 | 20.5% | 71.3% | ||
| Q2 24 | 21.2% | 71.4% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | 4.3% | ||
| Q3 25 | 15.6% | 7.0% | ||
| Q2 25 | 11.7% | 3.7% | ||
| Q1 25 | 3.6% | 5.4% | ||
| Q4 24 | 11.0% | 3.8% | ||
| Q3 24 | 14.7% | 4.6% | ||
| Q2 24 | 12.3% | 5.1% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | 3.3% | ||
| Q3 25 | 10.6% | 4.2% | ||
| Q2 25 | 8.2% | 4.6% | ||
| Q1 25 | -0.1% | 4.2% | ||
| Q4 24 | 5.7% | -0.3% | ||
| Q3 24 | 8.7% | 3.8% | ||
| Q2 24 | 6.9% | 1.2% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | $0.23 | ||
| Q3 25 | $0.30 | $0.30 | ||
| Q2 25 | $0.22 | $0.28 | ||
| Q1 25 | $0.00 | $0.25 | ||
| Q4 24 | $0.15 | $-0.02 | ||
| Q3 24 | $0.25 | $0.23 | ||
| Q2 24 | $0.19 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.8M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $275.1M | $161.6M |
| Total Assets | $587.7M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $93.9M | ||
| Q3 25 | $25.6M | $95.6M | ||
| Q2 25 | $31.2M | $81.3M | ||
| Q1 25 | $22.1M | $86.5M | ||
| Q4 24 | $19.2M | $84.7M | ||
| Q3 24 | $21.5M | $78.7M | ||
| Q2 24 | $17.7M | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | — | ||
| Q3 25 | $114.1M | — | ||
| Q2 25 | $124.6M | — | ||
| Q1 25 | $124.4M | — | ||
| Q4 24 | $126.1M | — | ||
| Q3 24 | $139.9M | — | ||
| Q2 24 | $147.6M | — |
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $161.6M | ||
| Q3 25 | $271.3M | $166.7M | ||
| Q2 25 | $261.3M | $163.7M | ||
| Q1 25 | $253.4M | $167.1M | ||
| Q4 24 | $246.6M | $161.0M | ||
| Q3 24 | $250.7M | $162.6M | ||
| Q2 24 | $240.3M | $156.4M |
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $261.1M | ||
| Q3 25 | $591.4M | $264.8M | ||
| Q2 25 | $602.1M | $254.9M | ||
| Q1 25 | $591.5M | $252.7M | ||
| Q4 24 | $585.1M | $240.9M | ||
| Q3 24 | $600.5M | $245.3M | ||
| Q2 24 | $597.8M | $235.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $9.9M |
| Free Cash FlowOCF − Capex | $517.0K | $7.6M |
| FCF MarginFCF / Revenue | 0.4% | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 0.77× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $22.5M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $9.9M | ||
| Q3 25 | $8.5M | $18.5M | ||
| Q2 25 | $13.9M | $4.3M | ||
| Q1 25 | $6.7M | $2.6M | ||
| Q4 24 | $20.6M | $12.2M | ||
| Q3 24 | $13.1M | $9.6M | ||
| Q2 24 | $17.1M | $1.3M |
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | $7.6M | ||
| Q3 25 | $6.5M | $16.8M | ||
| Q2 25 | $10.4M | $3.0M | ||
| Q1 25 | $3.9M | $1.5M | ||
| Q4 24 | $17.4M | $10.0M | ||
| Q3 24 | $10.4M | $7.9M | ||
| Q2 24 | $14.3M | $-2.0M |
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | 6.1% | ||
| Q3 25 | 4.8% | 13.1% | ||
| Q2 25 | 8.0% | 2.6% | ||
| Q1 25 | 3.1% | 1.3% | ||
| Q4 24 | 13.4% | 8.5% | ||
| Q3 24 | 7.7% | 6.9% | ||
| Q2 24 | 10.9% | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 1.9% | ||
| Q3 25 | 1.5% | 1.3% | ||
| Q2 25 | 2.7% | 1.2% | ||
| Q1 25 | 2.3% | 1.0% | ||
| Q4 24 | 2.5% | 1.9% | ||
| Q3 24 | 2.0% | 1.5% | ||
| Q2 24 | 2.2% | 3.0% |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | 2.41× | ||
| Q3 25 | 0.60× | 3.46× | ||
| Q2 25 | 1.31× | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 2.78× | — | ||
| Q3 24 | 1.12× | 2.21× | ||
| Q2 24 | 1.90× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLB
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
